David A. Siegel Cognition Therapeutics Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,000 shares of CGTX stock, worth $4,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,000

Holding current value

$4,840

% of portfolio

0.0%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.41 - $2.37 $4,510 - $26,070	11,000 New	11,000 $5,000
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.45 $18,750 - $43,125	-12,500 Reduced 44.48%	15,600 $33,000
Q1 2022 May 16, 2022	SELL	$2.41 - $6.9 $98,328 - $281,520	-40,800 Reduced 59.22%	28,100 $77,000
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $351,390 - $894,322	68,900 New	68,900 $435,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

6.52M

Call Options Held

Put Options Held

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $9.99M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account